Antiplatelet therapy in type 2 MI

Dr P.J. Devereaux is a professor in the Department of Health Research Methods, Evidence, and Impact and Department of Medicine and director of the Division of Cardiology at McMaster University.

What is the recommended antiplatelet therapy in a patient with type 2 myocardial infarction (MI)?

P.J. Devereaux, MD, PhD: With type 2 MI you have to ask the question, “Is this likely due to underlying significant atherosclerotic disease?” If it is, then certainly use dual antiplatelet therapy. Probably aspirin and ticagrelor would be used most commonly choice in today’s world with those patients.